Clinical trial · Observational
Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
NCT06914635CI-TRIAL-00088240recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Tumours | Liver Neoplasm | ALIAS | 0.90 |
| SARS CoV-2 | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Recovered subjects after SARS-CoV-2 infection
- label
- Patients with primary liver tumor.
Primary outcomes (1)
- measure
- The efficiency of antibodies will be evaluated toward SARS-CoV-2 and liver primary tumor cells by functional in vitro tests.
- timeFrame
- From enrollement to 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: Line 1: - Age \>18 at time of signing informed consent form * Signed informed consent form Line 2: - Primery liver tumor * Age \>18 at time of signing informed consent form * Signed informed consent form Exclusion Criteria: Line 1: - Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months * Chronic autoimmune or inflammatory diseases * Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies * Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse * HIV infection * Failure to sign informed consent form
References
Publications (0)
Data not yet available
No reference posted for this study.